Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

As global stock markets experience significant fluctuations in April 2025 due to world trade conflicts, more investors are seeking refuge in stable, dividend-paying stocks. The S& ...

TScan Therapeutics, Inc.’s TCRX share price has dipped by 5.81%, which has investors questioning if this is right time to buy ...

According to Benzinga Pro, Amgen's peer group average for short interest as a percentage of float is 5.89%, which means the company has less short interest than most of its peers. Did you know that ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Amgen (AMGN – Research Report), with a price target of ...

BYD's first-quarter profit leapt 100.4% from a year earlier, the fastest pace in nearly two years, as the Chinese electric ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Amgen (AMGN – Research Report), with a price target of $329.00. The company’s shares c ...

Fintel reports that on April 22, 2025, Cantor Fitzgerald initiated coverage of Amgen (NasdaqGS:AMGN) with a Overweight ...

Total Investment in the State to Exceed $1.4 Billion, 750 U.S. Jobs THOUSAND OAKS, Calif., April 25, 2025 /PRNewswire/ -- Amgen ...